{"transactions":[{"id":671176,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17951,"kind":"person","name":"Culverwell Anthony James","position":1,"cik":"0001693548","reported_name":"Culverwell Anthony James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Warrants (Right to Buy)","published_at":"2026-09-02T01:38:06.000Z","date":"2026-08-31","kind":"purchase","planned":false,"acquired":true,"shares":3073,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Purchased in Issuer's private placement of  ADSs with 50% warrant coverage.  The ADSs and accompanying ordinary warrants (\"Warrants\") were issued at a combined purchase price of $4.88."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchased in Issuer's private placement of  ADSs with 50% warrant coverage.  The ADSs and accompanying ordinary warrants (\"Warrants\") were issued at a combined purchase price of $4.88."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Ordinary Shares are represented by American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five (35) ordinary shares of the Issuer."}],"balance_after":3073,"derivative":{"exercise_price":6.1,"exercise_date":"2026-08-31","underlying":"ADS","underlying_shares":3073},"source":{"system":"sec-edgar","filing":"0001104659-26-104402","document":"tm2624615-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1693548/000110465926104402/tm2624615-1_4seq1.xml","form_type":"4"}},{"id":671175,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17951,"kind":"person","name":"Culverwell Anthony James","position":1,"cik":"0001693548","reported_name":"Culverwell Anthony James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2026-09-02T01:38:06.000Z","date":"2026-08-31","kind":"purchase","planned":false,"acquired":true,"shares":6146,"price":4.88,"value":29992.48,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Ordinary Shares are represented by American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five (35) ordinary shares of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Purchased in Issuer's private placement of  ADSs with 50% warrant coverage.  The ADSs and accompanying ordinary warrants (\"Warrants\") were issued at a combined purchase price of $4.88."}],"balance_after":40364,"source":{"system":"sec-edgar","filing":"0001104659-26-104402","document":"tm2624615-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693548/000110465926104402/tm2624615-1_4seq1.xml","form_type":"4"}},{"id":672971,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17951,"kind":"person","name":"Culverwell Anthony James","position":1,"cik":"0001693548","reported_name":"Culverwell Anthony James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2026-08-28T22:39:43.000Z","date":"2026-08-27","kind":"grant","planned":false,"acquired":true,"shares":31352,"price":5.15,"value":161462.8,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Ordinary Shares are represented by American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five (35) ordinary shares of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 27, 2026, the Issuer and the Reporting Person, entered into an exchange agreement, pursuant to which $161,461 of accrued interest outstanding (\"Outstanding Debt\") owed in connection with a note previously purchased by the Reporting Person was exchanged for 31,352 ADSs. The exchange agreement and the exchange of the Outstanding Debt for the ADSs was approved in advance by the Issuer's audit committee and board of directors."}],"balance_after":34218,"source":{"system":"sec-edgar","filing":"0001104659-26-103374","document":"tm2624320-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693548/000110465926103374/tm2624320-1_4seq1.xml","form_type":"4"}},{"id":916045,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17951,"kind":"person","name":"Culverwell Anthony James","position":1,"cik":"0001693548","reported_name":"Culverwell Anthony James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-02-06T22:20:19.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":21709,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."}],"balance_after":21709,"derivative":{"exercise_price":7.37,"expiration_date":"2036-02-04","underlying":"ADS","underlying_shares":21709},"source":{"system":"sec-edgar","filing":"0001104659-26-011617","document":"tm265448-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693548/000110465926011617/tm265448-6_4seq1.xml","form_type":"4"}},{"id":1056837,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17951,"kind":"person","name":"Culverwell Anthony James","position":1,"cik":"0001693548","reported_name":"Culverwell Anthony James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2025-08-25T20:05:52.000Z","date":"2025-08-21","kind":"grant","planned":false,"acquired":true,"shares":13682,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"date","element":"transactionDate","label":"F2","text":"The option grant was approved by the Compensation Committee and the Board on May 29, 2025, subject to shareholder approval. The Company's shareholder's approved this option grant on August 21, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."}],"balance_after":13682,"derivative":{"exercise_price":9.07,"expiration_date":"2035-05-28","underlying":"ADS","underlying_shares":13682},"source":{"system":"sec-edgar","filing":"0001104659-25-082515","document":"tm2524172-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693548/000110465925082515/tm2524172-2_4seq1.xml","form_type":"4"}},{"id":1125046,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17951,"kind":"person","name":"Culverwell Anthony James","position":1,"cik":"0001693548","reported_name":"Culverwell Anthony James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2025-06-03T20:00:21.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":7760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."}],"balance_after":7760,"derivative":{"exercise_price":9.07,"expiration_date":"2035-05-29","underlying":"ADS","underlying_shares":7760},"source":{"system":"sec-edgar","filing":"0001104659-25-055943","document":"tm2516320-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693548/000110465925055943/tm2516320-4_4seq1.xml","form_type":"4"}},{"id":1320968,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17951,"kind":"person","name":"Culverwell Anthony James","position":1,"cik":"0001693548","reported_name":"Culverwell Anthony James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series G Warrants (right to buy)","published_at":"2024-12-27T22:15:10.000Z","date":"2024-12-23","kind":"purchase","planned":false,"acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the \"Warrants.\""},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the \"Warrants.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Warrants were exercisable immediately, subject to a beneficial ownership cap."}],"balance_after":100000,"derivative":{"exercise_price":0.45,"exercise_date":"2024-12-23","expiration_date":"2029-12-24","underlying":"ADS","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-24-132185","document":"tm2431988-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1693548/000110465924132185/tm2431988-1_4seq1.xml","form_type":"4"}},{"id":1320967,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17951,"kind":"person","name":"Culverwell Anthony James","position":1,"cik":"0001693548","reported_name":"Culverwell Anthony James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series F Warrants (right to buy)","published_at":"2024-12-27T22:15:10.000Z","date":"2024-12-23","kind":"purchase","planned":false,"acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the \"Warrants.\""},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the \"Warrants.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Warrants were exercisable immediately, subject to a beneficial ownership cap."}],"balance_after":100000,"derivative":{"exercise_price":0.45,"exercise_date":"2024-12-23","expiration_date":"2026-12-23","underlying":"ADS","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-24-132185","document":"tm2431988-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1693548/000110465924132185/tm2431988-1_4seq1.xml","form_type":"4"}},{"id":1320966,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17951,"kind":"person","name":"Culverwell Anthony James","position":1,"cik":"0001693548","reported_name":"Culverwell Anthony James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-12-27T22:15:10.000Z","date":"2024-12-23","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":0.45,"value":45000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Reported securities are represented by American Depositary Shares (\"ADSs\"). Each ADS represents one ordinary share of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the \"Warrants.\""}],"balance_after":100317,"source":{"system":"sec-edgar","filing":"0001104659-24-132185","document":"tm2431988-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693548/000110465924132185/tm2431988-1_4seq1.xml","form_type":"4"}},{"id":1337202,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17951,"kind":"person","name":"Culverwell Anthony James","position":1,"cik":"0001693548","reported_name":"Culverwell Anthony James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2024-12-10T21:50:54.000Z","date":"2024-12-09","kind":"grant","planned":false,"acquired":true,"shares":50714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents one ordinary share of the Issuer."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four annual installments with 20% vesting on each of December 9, 2025, 2026 and 2027 and 40% vesting on December 9, 2028."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents one ordinary share of the Issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents one ordinary share of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents one ordinary share of the Issuer."}],"balance_after":50714,"derivative":{"exercise_price":0.78,"expiration_date":"2034-12-09","underlying":"ADS","underlying_shares":50714},"source":{"system":"sec-edgar","filing":"0001104659-24-127240","document":"tm2430519-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693548/000110465924127240/tm2430519-6_4seq1.xml","form_type":"4"}},{"id":1753832,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17951,"kind":"person","name":"Culverwell Anthony James","position":1,"cik":"0001693548","reported_name":"Culverwell Anthony James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-10-30T20:10:18.000Z","date":"2023-10-26","kind":"grant","planned":false,"acquired":true,"shares":7652,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four annual installments with 20% vesting on each of October 26, 2024, 2025 and 2026 and 40% vesting on October 26, 2027."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS."}],"balance_after":7652,"derivative":{"exercise_price":5.75,"exercise_date":"2024-10-26","expiration_date":"2033-10-26","underlying":"American Depositary Share","underlying_shares":7652},"source":{"system":"sec-edgar","filing":"0001104659-23-112565","document":"tm2329341-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693548/000110465923112565/tm2329341-3_4seq1.xml","form_type":"4"}},{"id":4251178,"issuer":{"id":12261,"kind":"organization","name":"Innocoll Holdings plc","symbol":"INNL"},"owners":[{"id":17951,"kind":"person","name":"Culverwell Anthony James","position":1,"cik":"0001693548","reported_name":"Culverwell Anthony James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant","published_at":"2017-07-26T23:00:58.000Z","date":"2017-07-24","kind":"disposition_to_issuer","acquired":false,"shares":57240,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Immediately prior to the Effective Time, the Reporting Person beneficially owned a warrant to purchase up to 57,240 Ordinary Shares (the \"Warrant\"). Pursuant to the terms of an Irrevocable Undertaking executed by the Reporting Person in connection with the Transaction Agreement, immediately prior to the Effective Time, the Warrant was terminated without any consideration being payable in respect thereof."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the Effective Time, the Reporting Person beneficially owned a warrant to purchase up to 57,240 Ordinary Shares (the \"Warrant\"). Pursuant to the terms of an Irrevocable Undertaking executed by the Reporting Person in connection with the Transaction Agreement, immediately prior to the Effective Time, the Warrant was terminated without any consideration being payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately prior to the Effective Time, the Reporting Person beneficially owned a warrant to purchase up to 57,240 Ordinary Shares (the \"Warrant\"). Pursuant to the terms of an Irrevocable Undertaking executed by the Reporting Person in connection with the Transaction Agreement, immediately prior to the Effective Time, the Warrant was terminated without any consideration being payable in respect thereof."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Immediately prior to the Effective Time, the Reporting Person beneficially owned a warrant to purchase up to 57,240 Ordinary Shares (the \"Warrant\"). Pursuant to the terms of an Irrevocable Undertaking executed by the Reporting Person in connection with the Transaction Agreement, immediately prior to the Effective Time, the Warrant was terminated without any consideration being payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":7,"expiration_date":"2019-06-15","underlying":"Ordinary Shares, par value $0.01 per share","underlying_shares":57240},"source":{"system":"sec-edgar","filing":"0001144204-17-038440","document":"v471491_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1693548/000114420417038440/v471491_4.xml","form_type":"4"}},{"id":4251177,"issuer":{"id":12261,"kind":"organization","name":"Innocoll Holdings plc","symbol":"INNL"},"owners":[{"id":17951,"kind":"person","name":"Culverwell Anthony James","position":1,"cik":"0001693548","reported_name":"Culverwell Anthony James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-07-26T23:00:58.000Z","date":"2017-07-24","kind":"disposition_to_issuer","acquired":false,"shares":14907,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the \"Options\"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the \"Options\"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the \"Options\"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the \"Options\"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":8.8,"expiration_date":"2026-03-30","underlying":"Ordinary Shares, par value $0.01 per share","underlying_shares":14907},"source":{"system":"sec-edgar","filing":"0001144204-17-038440","document":"v471491_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1693548/000114420417038440/v471491_4.xml","form_type":"4"}},{"id":4251176,"issuer":{"id":12261,"kind":"organization","name":"Innocoll Holdings plc","symbol":"INNL"},"owners":[{"id":17951,"kind":"person","name":"Culverwell Anthony James","position":1,"cik":"0001693548","reported_name":"Culverwell Anthony James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-07-26T23:00:58.000Z","date":"2017-07-24","kind":"disposition_to_issuer","acquired":false,"shares":8230,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the \"Options\"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the \"Options\"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the \"Options\"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the \"Options\"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":8.8,"expiration_date":"2026-03-30","underlying":"Ordinary Shares, par value $0.01 per share","underlying_shares":8230},"source":{"system":"sec-edgar","filing":"0001144204-17-038440","document":"v471491_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1693548/000114420417038440/v471491_4.xml","form_type":"4"}},{"id":4251175,"issuer":{"id":12261,"kind":"organization","name":"Innocoll Holdings plc","symbol":"INNL"},"owners":[{"id":17951,"kind":"person","name":"Culverwell Anthony James","position":1,"cik":"0001693548","reported_name":"Culverwell Anthony James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-07-26T23:00:58.000Z","date":"2017-07-24","kind":"disposition_to_issuer","acquired":false,"shares":11659,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the \"Options\"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the \"Options\"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the \"Options\"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the \"Options\"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":8.8,"expiration_date":"2026-03-30","underlying":"Ordinary Shares, par value $0.01 per share","underlying_shares":11659},"source":{"system":"sec-edgar","filing":"0001144204-17-038440","document":"v471491_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1693548/000114420417038440/v471491_4.xml","form_type":"4"}},{"id":4251174,"issuer":{"id":12261,"kind":"organization","name":"Innocoll Holdings plc","symbol":"INNL"},"owners":[{"id":17951,"kind":"person","name":"Culverwell Anthony James","position":1,"cik":"0001693548","reported_name":"Culverwell Anthony James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.01 per share","published_at":"2017-07-26T23:00:58.000Z","date":"2017-07-24","kind":"disposition_to_issuer","acquired":false,"shares":291566,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Immediately prior to the Effective Time (as defined below), the Reporting Person beneficially owned 291,566 ordinary shares of the Issuer, par value $0.01 per share (\"Ordinary Shares\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Transaction Agreement by and among the Issuer, Gurnet Point L.P., a Delaware limited partnership acting through its general partner Waypoint International GP LLC (\"Gurnet Point\"), and Lough Ree Technologies Limited, an Irish private limited company and wholly-owned subsidiary of Gurnet Point (the \"Transaction Agreement\"), each Ordinary Share that was beneficially owned by the Reporting Person immediately prior to the effective time of the scheme (the \"Effective Time\") now represents the right to receive (i) $1.75 in cash and (ii) a contingent value right which represents a contractual right to receive payments up to a maximum aggregate amount of $4.90 in cash upon, and subject to, the occurrence of certain events, without interest and net of applicable tax withholdings."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Pursuant to the terms of the Transaction Agreement by and among the Issuer, Gurnet Point L.P., a Delaware limited partnership acting through its general partner Waypoint International GP LLC (\"Gurnet Point\"), and Lough Ree Technologies Limited, an Irish private limited company and wholly-owned subsidiary of Gurnet Point (the \"Transaction Agreement\"), each Ordinary Share that was beneficially owned by the Reporting Person immediately prior to the effective time of the scheme (the \"Effective Time\") now represents the right to receive (i) $1.75 in cash and (ii) a contingent value right which represents a contractual right to receive payments up to a maximum aggregate amount of $4.90 in cash upon, and subject to, the occurrence of certain events, without interest and net of applicable tax withholdings."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001144204-17-038440","document":"v471491_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693548/000114420417038440/v471491_4.xml","form_type":"4"}}]}